Pfizer's Latest Immunotherapy Deal Could Be Great News for This … – Motley Fool


Motley Fool

Pfizer’s Latest Immunotherapy Deal Could Be Great News for This …
Motley Fool
There’s renewed interest in an immuno-oncology target that just so happens to match Agenus’ lead (unpartnered) drug candidate.

and more »

Read More…

Share This: